Find out all about Recce

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is pioneering the development and commercialisation of a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens.

Latest Announcements
View Archive
Tackling Superbugs - RECCE 327

There have been no new classes of antibiotics on the market for over 30 years - RECCE® 327 has the potential to break that mould. RECCE® 327 is a synthetic polymer, designed to target bacteria that cause infectious disease – including ones that are resistant to current antibiotics – the superbugs. Bacterial infections of the blood are deadly and affect an estimated 30 million people world-wide every year - this is where RECCE® 327 is designed to act. RECCE® 327 is designed to be administered through injection so it can quickly spread through the blood stream.

RECCE® 327 is designed to adhere to the outer cell wall of the infectious bacteria through hydrophobic interactions. This weakens the cell wall and internal pressures from within the cell cause the bacteria to burst. The body’s own mechanisms can then clear the infection. Normal non-bacterial cells remain intact as they do not contain high internal pressures.

Tests have shown RECCE® 327 is fast acting and as a broad spectrum antibiotic is effective against gram positive and gram negative bacteria including antibiotic resistant superbugs. Following regulatory requirements for new antibiotics, safety and efficacy tests will continue to urgently explore RECCE® 327’s ability to address the global threat posed by superbugs. Together we can make antibiotic resistance history – visit RECCE.com.au to find out more.

Learn More

Follow the progress of our unique Australian innovation

Contact Us Today

Sign up for news and updates

Receive news and information direct to your inbox.